GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » EV-to-Revenue

Cabio Biotech (Wuhan) Co (SHSE:688089) EV-to-Revenue : 5.08 (As of Jun. 03, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cabio Biotech (Wuhan) Co's enterprise value is ¥2,402.8 Mil. Cabio Biotech (Wuhan) Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥473.1 Mil. Therefore, Cabio Biotech (Wuhan) Co's EV-to-Revenue for today is 5.08.

The historical rank and industry rank for Cabio Biotech (Wuhan) Co's EV-to-Revenue or its related term are showing as below:

SHSE:688089' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.13   Med: 11.62   Max: 24.12
Current: 5.08

During the past 11 years, the highest EV-to-Revenue of Cabio Biotech (Wuhan) Co was 24.12. The lowest was 4.13. And the median was 11.62.

SHSE:688089's EV-to-Revenue is ranked better than
61.16% of 1035 companies
in the Biotechnology industry
Industry Median: 8.2 vs SHSE:688089: 5.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-03), Cabio Biotech (Wuhan) Co's stock price is ¥15.25. Cabio Biotech (Wuhan) Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2.74. Therefore, Cabio Biotech (Wuhan) Co's PS Ratio for today is 5.57.


Cabio Biotech (Wuhan) Co EV-to-Revenue Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co EV-to-Revenue Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.63 12.05 19.08 11.42 6.32

Cabio Biotech (Wuhan) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.66 6.97 6.27 6.32 4.73

Competitive Comparison of Cabio Biotech (Wuhan) Co's EV-to-Revenue

For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cabio Biotech (Wuhan) Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cabio Biotech (Wuhan) Co's EV-to-Revenue falls into.



Cabio Biotech (Wuhan) Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cabio Biotech (Wuhan) Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2402.761/473.062
=5.08

Cabio Biotech (Wuhan) Co's current Enterprise Value is ¥2,402.8 Mil.
Cabio Biotech (Wuhan) Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥473.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cabio Biotech (Wuhan) Co  (SHSE:688089) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cabio Biotech (Wuhan) Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.25/2.737
=5.57

Cabio Biotech (Wuhan) Co's share price for today is ¥15.25.
Cabio Biotech (Wuhan) Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.74.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cabio Biotech (Wuhan) Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co (SHSE:688089) Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Xiao Min senior management
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co (SHSE:688089) Headlines

No Headlines